← Eichor
Study identifier: NCT06943599 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Strategies for Improving Linkage-to-Care After Eye Disease Screening

Condition: Age Related Macular Degeneration · Diabetic Retinopathy · Glaucoma  ·  Sponsor: University of California, San Francisco

PhaseNA
Planned participants3000
Who can joinAll sexes, 60 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this randomized, parallel-group, controlled trial is to compare methods of improving linkage-to-care for participants in the Village Integrated Eye Worker II (VIEW II) trial who are referred to the eye hospital following eye disease screening. Participants who are referred to the hospital at an eye screening visit will be randomized to three different linkage-to-care interventions: (1) text message reminders, (2) reminders from health workers, or (3) no intervention. The primary outcome of the trial will be whether or not the participant presented to the eye hospital for a referral visit by 21 days following screening.

This description comes directly from the study's public registry record.

Talk to the study team

Jeremy Keenan, MD, MPH  ·  (415) 476-1442  ·  jeremy.keenan@ucsf.edu

Krisianne Aromin  ·  krisianne.aromin@ucsf.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of California, San FranciscoSan Francisco, California, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06943599